Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

AIDS. 2004 Nov 19;18(17):2337-9. doi: 10.1097/00002030-200411190-00019.

Abstract

Highly active antiretroviral therapy (HAART) may be associated with adverse pregnancy outcomes. Among 4372 live births in the European Collaborative Study, the prematurity rate increased to 24.9% in 2000-2004. Antenatal HAART use initiated pre-pregnancy was strongly associated with prematurity (AOR 2.05, 95% CI 1.43, 2.95), particularly severe prematurity. The implication of increased prematurity is evidenced in high neonatal mortality in these groups (0.66% for infants at 34-36 weeks and 7.37% at < 34 weeks' gestation).

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antiretroviral Therapy, Highly Active / methods*
  • Child
  • Female
  • Gestational Age
  • HIV Infections / drug therapy*
  • Humans
  • Infant Mortality
  • Infant, Low Birth Weight
  • Infant, Newborn
  • Infant, Premature*
  • Middle Aged
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Prenatal Care / methods
  • Risk Factors